Skip to main content

Immucell Value Stock - Dividend - Research Selection

Immucell

ISIN: US4525253062 , WKN: 885825

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Zacks Initiates Coverage of ImmuCell With Neutral Recommendation

2024-12-04
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.

The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell

2024-12-04
Amazon.com, Stryker, Lam Research and ImmuCell are included in this Analyst Blog.

Top Research Reports for Amazon, Stryker & Lam Research

2024-12-03
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Stryker Corporation (SYK) and Lam Research Corporation (LRCX), as well as a micro-cap stock, ImmuCell Corporation (ICCC).

ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges

2024-11-19
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.

ImmuCell Third Quarter 2024 Earnings: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023)

2024-11-16
ImmuCell ( NASDAQ:ICCC ) Third Quarter 2024 Results Key Financial Results Revenue: US$6.01m (up 11% from 3Q 2023). Net...

ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript

2024-11-14
ImmuCell Corporation (NASDAQ:ICCC) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ETCompany ParticipantsJoe Diaz - Lytham PartnersMichael...

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

2024-11-13
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights: Product sales increased 11% over the comparable quarter in 2023.Product sales increased

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

2024-11-07
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, No

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

2024-10-08
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring th

ImmuCell announces preliminary results for Q3 2024

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.